{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-109387","form_type":"8-K","ticker":"NAMS","cik":"0001936258","company_name":"NewAmsterdam Pharma Co N.V.","filed_at":"2025-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.642802+00:00","generated_at":"2026-05-17T12:35:29.048789+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"NewAmsterdam enters supply agreement with Menarini for obicetrapib products","bullets":["Supply Agreement dated Aug 12, 2025 with Menarini for obicetrapib monotherapy and obicetrapib/ezetimibe fixed-dose combo.","Subsidiary will be exclusive supplier initially; price based on cost of goods sold plus a specified mark-up.","Parties to initiate manufacturing transfer to Menarini; subsidiary grants non-exclusive license for manufacturing.","Supply term runs with License Agreement (from June 2022); subsidiary can terminate on 120 days’ notice after transfer or 2 years.","Either party may terminate for uncured material breach, insolvency, or force majeure exceeding 6 months."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-109387","json":"https://secwatch.observer/filing/0000950170-25-109387.json","markdown":"https://secwatch.observer/filing/0000950170-25-109387.md","text":"https://secwatch.observer/filing/0000950170-25-109387.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/0000950170-25-109387-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1936258/000095017025109387/nams-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:35:29.048789+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}